Safety and feasibility of instituting a robotic pancreas program in the Australian setting: a case series and narrative review

Abstract

AbstractBackgroundMinimally invasive pancreatic resection has been gathering interest over the last decade due to the technical demands and high morbidity associated with these typically open procedures. We report our experience with robotic pancreatectomy within an Australian context.MethodsAll patients undergoing robotic distal pancreatectomy (DP) and pancreaticoduodenectomy (PD) at two Australian tertiary academic hospitals between May 2014 and December 2020 were included.ResultsSixty‐two patients underwent robotic pancreatectomy during the study period. Thirty‐four patients with a median age of 68 years (range 42–84) were in the PD group whilst the DP group included 28 patients with a median age of 60 years (range 18–78). Thirteen patients (46.4%) in the DP group had spleen‐preserving procedures. There were 13 conversions (38.2%) in the PD group whilst 0 conversions occurred in the DP group. The Clavien‐Dindo grade ≥III complication rate was 26.4% and 17.9% in the PD and DP groups, respectively. Two deaths (5.9%) occurred within 90‐days in the PD group whilst none were observed in the DP group. The median length of hospital stay was 11.5 days (range 4–56) in the PD group and 6 days (range 2–22) in the DP group.ConclusionRobotic pancreatectomy outcomes at our institution are comparable with international literature demonstrating it is both safe and feasible to perform. With improved access to this platform, robotic pancreas surgery may prove to be the turning point for patients with regards to post‐operative complications as more experience is obtained.